Search Results 791-800 of 16881 for Amphotericin B
... B cell malignancies by engineering T cells to recognize B cell specific tumor markers; however, attempts to treat solid tumors with CAR T-cells have ...
Part B will enroll adult subjects with CF currently on stable ORKAMBI® background therapy for a minimum of 3 months into a Phase II treatment group ... Cystic ...
Taylor MM, Collier MG, Winscott MM, Mickey T, England B. Reticence to prescribe: utilization of expedited partner therapy among obstetrics providers in Arizona.
Andrew J. Bentall, M.B., Ch.B., M.D.. Rochester, MN. Area of Focus: Transplant, Pancreas transplant, Kidney transplant, Living donor kidney ...
The purpose of this study is to provide access to CTL019 through Managed Access Program (MAP) for acute lymphoblastic leukemia (ALL) or diffuse large b-cell ...
Tariq A, Trivedi S, Urooj A, Ramasamy G, Fathizadeh S, Stib M, Tan N, Patel B, Banerjee I. Patient-centric summarization of radiology findings using two ...
Find a doctor whose last name begins with the letter B B · Find a doctor whose ... Areas of focus: Bone marrow transplant, CAR-T cell therapy, Myelodysplastic ...
This medicine is available without a prescription. This product is available in the following dosage forms: Suspension; Tablet, Chewable; Capsule, Liquid Filled ...
AZD0486 As Monotherapy In Participants With Relapsed/Refractory (R/R) B-cell NHL. Rochester, Minn. This is a Phase 2 global, multi-center, open-label study ...
... B-cell blood cancers. Susan Buckles. October 10, 2023. Preparing to biomanufacture a new CAR-T cell therapy for B-cell cancers featured. Research. Preparing ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Your donation powers the future of medicine and helps save lives.